* Vincerx Pharma Inc VINC.OQ VINC.O is expected to show
no
change in quarterly revenue when it reports results on November
12 (estimated) for the period ending September 30 2024
*
* LSEG's mean analyst estimate for Vincerx Pharma Inc is
for a
loss of 22 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Vincerx
Pharma
Inc is $6.00, above its last closing price of $0.32.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.19 -0.20 -0.05 Beat 75.6
Mar. 31 2024 -0.24 -0.23 -0.58 Missed -146.8
Dec. 31 2023 -0.37 -0.23 Beat 37.3
Sep. 30 2023 -0.46 -0.46 -0.46 Met -0.7
Jun. -0.61 -0.60 -0.52 Beat 12.9
30 2023
Mar. 31 2023 -0.52 -0.52 -0.68 Missed -30.8
Dec. 31 2022 -0.61 -0.65 Missed -5.7
Sep. 30 2022 -0.64 -0.55 -0.80 Missed -44.8
This summary was machine generated November 8 at 16:08 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)